NSE-listed pharmaceutical companies offering contract development and manufacturing (CDMO) services to global drug makers — from API synthesis to finished dosage forms.
Sectors represented: Healthcare
Contract Research Development and Manufacturing Organizations (CRDMO). One-stop service solution is a business model of pharmaceutical contract organizations that provides services. covering entire value chain. 1. 1. 1. 2 h Development and Manufacturing Organizations (CRDMO). One-stop service solution is a business model of pharmaceutical contract organizations that provides services.
Robust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business. 17 obust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business...
This shift is further reinforced by transitioning to. an asset-light model, which reduces operating and capital. expenditures. locate resources. more effectively toward innovation and commercial. growth. This shift is further reinforced by transitioning to. an asset-light model, which reduces operating and capital. expenditures. By leveraging CDMOs' streamlined procedures.
CDMO / CMO. 8. ❏Sustainable supply for APIs/NCEs/Intermediates in commercial scale. ❏Global regulatory accreditations (USFDA ,EUGMP, EDQM, KFDA, COFEPRIS). ❏EHS and Quality are the highest priority. nue. CDMO / CMO. 8. ❏Sustainable supply for APIs/NCEs/Intermediates in commercial scale. ❏Global regulatory accreditations (USFDA ,EUGMP, EDQM, KFDA, COFEPRIS).
The global pharmaceutical contract development and manufacturing. organisation (CDMO) market is experiencing significant growth, valued. at US$166.0 Billion in 2025 and projected to reach US$293.6 Billion global pharmaceutical contract development and manufacturing. organisation (CDMO) market is experiencing significant growth, valued.
Within this landscape, obesity emerged. as one of the fastest-growing therapy areas globally,. supported by the rapid adoption of GLP-1 therapies. Growing demand for obesity and metabolic disorder. treatments continues to support the expansion of the GLP-. 1 therapy market. as globally,. supported by the rapid adoption of GLP-1 therapies. Growing demand for obesity and metabolic disorder.
Integrated CDMO Player present along the entire value chain from building blocks to commercialization and product launch stage. Large Scale Mfg. ACITIES. CLOSE PROXIMITY. TO CLIENTS WITH. GLOBAL PRESENCE. Integrated CDMO Player present along the entire value chain from building blocks to commercialization and product launch stage. Large Scale Mfg.
We offer a. diverse and expanding range. of pharmaceutical products,. meticulously developed to. meet the evolving clinical and. treatment needs of patients. worldwide. Our portfolio encompasses a. broad array of pharmaceutical. solutions, comprising of an. array of generic formulations developed to. meet the evolving clinical and. treatment needs of patients. worldwide.
Contract Development and Manufacturing Organization. (CDMO). CDMO Market. The global CDMO market (small + large molecules) was valued at USD ~130 ch. partner rather than a transactional service provider. Contract Development and Manufacturing Organization. (CDMO). CDMO Market. The global CDMO market (small + large molecules) was valued at USD ~130.
Significant steps have been taken to improve raw material. and utilities consumption and increase manufacturing. efficiency. Building long-term relationships with key customers by. offering improved quality and service experience. Building economies of scale in manufacturing, distribution. channels and procurement to maintain cost advantage and. sustained entry barrier.
This is. followed by pre-clinical and clinical development services, including. pharmacokinetic and toxicology studies, clinical trial support,. formulation development and process optimisation. d by pre-clinical and clinical development services, including. pharmacokinetic and toxicology studies, clinical trial support,. formulation development and process optimisation. In later stages,.
Akums revenue. 4. IndianCDMO Market. Source: Frost and Sullivan Report on Indian Pharma CDMO (details in Akums RHP). 5. Indian Pharma Market. (INR ‘000 Cr.). Large Indian domestic pharma. opportunity. 132. 198. 285 revenue. 4. IndianCDMO Market. Source: Frost and Sullivan Report on Indian Pharma CDMO (details in Akums RHP). 5. Indian Pharma Market. (INR ‘000 Cr.). Large Indian domestic pharma.
Pharmaceutical Exports. India’s formulation exports are expected to grow at a. CAGR of 6-8% from fiscal 2023 to fiscal 2025, as against. the growth rate of 8-9% over the previous five years. aceutical Exports. India’s formulation exports are expected to grow at a. CAGR of 6-8% from fiscal 2023 to fiscal 2025, as against. the growth rate of 8-9% over the previous five years.
Process DevelopmentQuality & Regulatory ServicesDrug Substance Drug Product. . Mammalian and microbial platforms. . Single-use bioreactors for lower cost, reduced. contamination risk and higher uptime. . Clinical batches to high-speed commercial. lines inc. ug Substance Drug Product. . Mammalian and microbial platforms. . Single-use bioreactors for lower cost, reduced.
India remains a major supplier of affordable generic medicines worldwide and has the highest number of USFDA-compliant pharmaceutical. manufacturing facilities outside the United States. Pharmaceutical exports reached approximately Rs. generic medicines worldwide and has the highest number of USFDA-compliant pharmaceutical. manufacturing facilities outside the United States.
Rising compliance thresholds. across major markets are likely to further consolidate. participation toward chemistry strong, regulatory. reliable suppliers. Global Contract Development and Manufacturing. Organisation (CDMO) Industry kets are likely to further consolidate. participation toward chemistry strong, regulatory. reliable suppliers. Global Contract Development and Manufacturing.
ISB 2001 DATA PRESENTATION AT ASH2024. ▪IGI presented first-time data from its Phase 1 study of ISB 2001 in an oral presentation at the 66th American Society of Hematology. (ASH) Annual Meeting in San Diego, CA. The oral presentation detailed out the results from the dose-escalation portion of the study.